^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CD22/CD19 CAR T

i
Other names: CD22/CD19 CAR T
Associations
Company:
The First Affiliated Hospital of Soochow University
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
4ms
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (clinicaltrials.gov)
P1/2, N=35, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: May 2024 --> Dec 2024
Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22/CD19 CAR T
1year
Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT "Sandwich" Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia (ASH 2023)
Afterwards, autologous CAR T-cells targeting CD22 and CD19 (CAR-T 1, co-stimulatory molecule was 4-1BB and infusion dose was 5×106/kg, respectively) were sequential infused after lymphodepletion chemotherapy with fludarabine and cytophosphamide...Two patients with Ph- B-ALL relapsed at 5 and 6 months after auto-HSCT and were treated with blinatumomab... Our preliminary study demonstrated that CD22/CD19 CAR-T and Auto-HSCT "Sandwich" strategy as a consolidation strategy showed favorable safety and efficacy in Ph- B-ALL. CD22/CD19 CAR-T resulted in deeper remission before transplantation. The new strategy may benefit patients from LFS and OS.
Clinical • IO biomarker
|
CD22 (CD22 Molecule)
|
Blincyto (blinatumomab) • fludarabine IV • CD22/CD19 CAR T • ssCART-19
2years
Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia (ASH 2022)
The main purpose of this study is to observe the safety and efficacy of CD22/CD19 CAR-T bridging to autologous stem cell transplantation (auto-HSCT) in B-ALL patients...Afterwards, autologous CAR T-cells targeting CD22 and CD19 (co-stimulatory molecule was 4-1BB and infusion dose was 5×106/kg, respectively) were sequential infused after lymphodepletion chemotherapy with fludarabine and cytophosphamide... Our preliminary study demonstrated that autologous CD22 and CD19 CAR-T cell infusion bridging auto-HSCT as a consolidation strategy showed favorable safety and efficacy in B-ALL. The harvest of autologous stem cells after CAR-T cell therapy allows the persistence of CAR-T cells in the stem cells, which may explain the persistence of CAR-T cells after autologous transplantation despite the myeloablative conditioning regimen used in our study.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
fludarabine IV • CD22/CD19 CAR T • ssCART-19
over2years
CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (clinicaltrials.gov)
P1/2, N=35, Recruiting, The First Affiliated Hospital of Soochow University
New P1/2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
CD22/CD19 CAR T